Challenges and Opportunities for Kaposi Sarcoma Clinical Trials in Sub-Saharan Africa: A Review
Preprint
- 20 October 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Kaposi sarcoma is a vascular tumor that remains a significant global public health challenge, with approximately 70% of cases occurring in sub-Saharan Africa (SSA), where Human Immunodeficiency Virus (HIV) and Human Herpesvirus 8 (HHV-8) are highly prevalent. Furthermore, relatively few clinical trials have been conducted in SSA, potentially delaying the development of more effective interventions for this cancer. This review evaluated completed prospective clinical trials for the treatment of HIV-associated Kaposi sarcoma (KS) conducted in sub-Saharan Africa (SSA) and highlighted the complementary role of investigator-initiated clinical trials in drug development. We searched the internet and medical databases using relevant key terms. We identified 171 indexed HIV-KS clinical trials worldwide and extracted seven that were conducted in SSA between 1984 and July 2022. The first trial took place in Zimbabwe and was published in 2005. The second and third trials were conducted in South Africa and published in 2008 and 2012, respectively. The fourth and sixth trials were done in Kenya, Uganda, South Africa, Zimbabwe, and Brazil, and were published in 2018 and 2020. The fifth was an investigator-initiated trial (IIT) done in Kenya and published in 2018 and 2019. The sixth trial featured the largest sample size and the most diverse study population. The seventh evaluated the effectiveness of locally sourced compression bandages for HIV-KS leg lymphedema in Kenya and was published in 2022. The number of clinical trials for interventions to treat HIV-KS in SSA remains disproportionate to the high burden of disease in the region. Highlighting research gaps may stimulate interest in studies aimed at finding a cure for HIV-KS in sub-Saharan Africa.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022The Oncologist, 2025
- Reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patientsEBioMedicine, 2024
- Epidemiology of Kaposi’s sarcoma in sub-Saharan AfricaCancer Epidemiology, 2022
- Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trialThe Lancet, 2020
- Recurrence and Occurrence of Kaposi’s Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV ViremiaClinical Infectious Diseases, 2019
- As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical TrialClinical Infectious Diseases, 2018
- A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Investigator‐initiated pragmatic trials in developing countries – much needed but much ignoredBritish Journal of Clinical Pharmacology, 2008
- Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma – A prospective randomized trialRadiotherapy and Oncology, 2008
- Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: Results of a randomized quality of life focused clinical trialInternational Journal of Cancer, 2004